Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2025-05-31 DOI:10.3390/curroncol32060325

Kaili Jin, Xianlei Lin, Xiaoting Xia, Huiling Ye, Dan Yang, Ying Fan, Qiuhua Sun, Rongyun Wang

{"title":"Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.","authors":"Kaili Jin, Xianlei Lin, Xiaoting Xia, Huiling Ye, Dan Yang, Ying Fan, Qiuhua Sun, Rongyun Wang","doi":"10.3390/curroncol32060325","DOIUrl":null,"url":null,"abstract":"Background: Platinum-based chemotherapy significantly increases the risk of nausea and vomiting, which can impair the treatment's efficacy and the patient's quality of life. This meta-analysis examines the incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting (PINV) in patients treated with this chemotherapy.Methods: This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. We conducted a literature search in the databases PubMed, Embase, Web of Science, WanFang, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), and Chinese Medical Association Journal Database (CMAJD) through to 20 January 2025. Studies that reported the incidence and identified risk factors of nausea and vomiting specifically in patients receiving platinum-based chemotherapy were included in the review. The data were extracted independently by two reviewers. The odds ratios (ORs) for each risk factor were calculated from the included studies. Sensitivity analyses and additional subgroup analyses were performed to ensure the robustness of our findings.Results: This meta-analysis included 32 studies involving 14,207 participants. Female sex (OR = 2.363, 95% CI = 1.363-4.096, p = 0.002), anxiety (OR = 1.689, 95% CI = 1.057-2.700, p = 0.028), fatigue (OR = 1.413, 95% CI = 1.145-1.744, p = 0.001), motion sickness (OR = 1.816, 95% CI = 1.266-2.605, p = 0.001), and a history of vomiting during chemotherapy (OR = 2.728, 95% CI = 1.468-5.069, p = 0.002) were significantly associated with an increased risk of PINV.Conclusion: Female sex, anxiety, fatigue, motion sickness, and a history of vomiting during chemotherapy increase the risk of PINV during platinum-based treatments.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191659/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32060325","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Platinum-based chemotherapy significantly increases the risk of nausea and vomiting, which can impair the treatment's efficacy and the patient's quality of life. This meta-analysis examines the incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting (PINV) in patients treated with this chemotherapy.

Methods: This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. We conducted a literature search in the databases PubMed, Embase, Web of Science, WanFang, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), and Chinese Medical Association Journal Database (CMAJD) through to 20 January 2025. Studies that reported the incidence and identified risk factors of nausea and vomiting specifically in patients receiving platinum-based chemotherapy were included in the review. The data were extracted independently by two reviewers. The odds ratios (ORs) for each risk factor were calculated from the included studies. Sensitivity analyses and additional subgroup analyses were performed to ensure the robustness of our findings.

Results: This meta-analysis included 32 studies involving 14,207 participants. Female sex (OR = 2.363, 95% CI = 1.363-4.096, p = 0.002), anxiety (OR = 1.689, 95% CI = 1.057-2.700, p = 0.028), fatigue (OR = 1.413, 95% CI = 1.145-1.744, p = 0.001), motion sickness (OR = 1.816, 95% CI = 1.266-2.605, p = 0.001), and a history of vomiting during chemotherapy (OR = 2.728, 95% CI = 1.468-5.069, p = 0.002) were significantly associated with an increased risk of PINV.

Conclusion: Female sex, anxiety, fatigue, motion sickness, and a history of vomiting during chemotherapy increase the risk of PINV during platinum-based treatments.

查看原文本刊更多论文

铂类化疗引起的恶心和呕吐的发生率和危险因素：系统回顾和荟萃分析。

背景：铂基化疗明显增加恶心和呕吐的风险，影响治疗效果和患者的生活质量。本荟萃分析探讨了接受铂类化疗的患者中铂类化疗引起的恶心和呕吐（PINV）的发生率和危险因素。方法：根据PRISMA 2020指南进行系统评价和荟萃分析。我们在PubMed、Embase、Web of Science、万方、中国科技期刊数据库（VIP）、中国知网（CNKI）和中华医学会期刊数据库（CMAJD）进行了文献检索，检索时间截止到2025年1月20日。研究报告的发病率和确定的恶心和呕吐的危险因素，特别是在接受铂类化疗的患者被纳入审查。数据由两位审稿人独立提取。从纳入的研究中计算每个危险因素的优势比（ORs）。进行敏感性分析和额外的亚组分析以确保我们研究结果的稳健性。结果：本荟萃分析包括32项研究，涉及14207名参与者。女性（OR = 2.363, 95% CI = 1.363-4.096, p = 0.002）、焦虑（OR = 1.689, 95% CI = 1.057-2.700, p = 0.028）、疲劳（OR = 1.413, 95% CI = 1.145-1.744, p = 0.001）、晕动病（OR = 1.816, 95% CI = 1.266-2.605, p = 0.001）和化疗期间呕吐史（OR = 2.728, 95% CI = 1.468-5.069, p = 0.002）与PINV风险增加显著相关。结论：女性、焦虑、疲劳、晕动病和化疗期间的呕吐史增加了铂基治疗期间PINV的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.